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Abstract   
Spiradenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and 
potential for malignant transformation and aggressive behaviour. We present the genomic analysis of 75 
samples from 57 representative patients including 15 cylindromas, 17 spiradenomas, 2 cylindroma-
spiradenoma hybrid tumors, and 24 low- and high-grade spiradenocarcinoma cases, together with 
morphologically benign precursor regions of these cancers. We reveal somatic or germline alterations of 
the CYLD gene in 15/15 cylindromas and 5/17 spiradenomas, yet only 2/24 spiradenocarcinomas. Notably, 
we find a recurrent missense mutation (22 tumors, 18 patients) in the kinase domain of the ALPK1 gene in 
spiradenomas and spiradenocarcinomas, which is mutually exclusive from mutation of CYLD and can 
activate the NF-κB pathway in reporter assays. In addition, we show that high-grade spiradenocarcinomas 
carry loss-of-function TP53 mutations, while cylindromas may have disruptive mutations in DNMT3A. 
Thus, we reveal the genetic landscape of adnexal tumors and therapeutic targets.   
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Introduction 
There are two main groups of adnexal tumors; those that are associated with the female reproductive system 
including tissues such as the ovaries, fallopian tubes and the connective tissues that surround these 
structures, and skin adnexal tumors of cutaneous origin. The word “adnexa” is Latin in origin and refers to 
the appendages of an organ. Spiradenoma and cylindroma are closely related benign skin adnexal tumors 
with sweat gland differentiation. They show histological similarities and may represent part of a 
morphological spectrum, further evidenced by rare spiradenoma-cylindroma hybrid tumors. The majority 
of tumors are sporadic and present as solitary nodules. Spiradenomas show a predilection for the 
extremities, while cylindromas commonly occur on the head and neck1. Occasionally, they may be multiple 
in the setting of the Brooke-Spiegler syndrome (BSS), a rare autosomal-dominant inherited disorder 
characterized by cylindromas, spiradenomas and/or trichoepitheliomas in individuals with germline 
mutation of the CYLD gene 2. Malignant transformation in spiradenoma (spiradenocarcinoma) and, less 
frequently, cylindroma (cylindrocarcinoma) is a rare event. Histologically these tumors are composed of a 
benign precursor and a morphologically distinct malignant component, which may be further subdivided 
into low-grade or high-grade3. The morphology of these tumors appears to be a good predictor of outcome. 
Morphologically low-grade tumors have potential for local recurrence, while disseminated disease and 
disease-related mortality is largely limited to high-grade carcinomas 3, 4, 5, 6. Little is known about the 
underlying genetic events that drive these tumors. Cylindromas are characterized by mutations in CYLD 
and approximately two thirds of sporadic cylindromas have also been reported to carry the MYB-NFIB 
fusion gene, which leads to overexpression of MYB, analogous to adenoid cystic carcinoma 7, 8, 9. No genetic 
data are available for spiradenomas and the events leading to malignant transformation and to the more 
aggressive behavior of the high-grade tumors are largely unknown. As yet, only mutations in the TP53 gene 
have been reported in the malignant tumors 10, 11.  
 
To improve understanding of these rare diseases we perform a comprehensive genomic characterisation 
of samples from a large collection of representative patients and detail the driver gene landscape and 
biological processes that are operative. Notably, we find a hotspot driver mutation in ALPK1 that defines 
spiradenoma and spiradenocarcinoma cases.  
 
Results 
Sample ascertainment and whole exome sequencing 
Samples were obtained through the University of Edinburgh Tissue Bank with ethical approval obtained 
under REC 15/ES/0094. Analysis of these samples was also approved by the Sanger Human Materials and 
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Data Management Committee (HMDMC). Cases were independently reviewed by two dermatopathologists 
to confirm diagnoses. In total 75 samples underwent next-generation sequencing, 52 with paired adjacent 
normal/germline DNA (from 42 patients), while the remaining 23 samples (15 patients) without matched 
normal/germline DNA were used as a validation cohort (Supplementary Data 1). Capillary sequencing 
was also performed on 10 cases from 10 additional patients to validate a hotspot mutation as described 
below. A full breakdown of the samples used at the various stages of analysis and available clinical 
characteristics of each patient is provided in Supplementary Data 1. Briefly, high- and low-grade 
spiradenocarcinoma, benign spiradenoma and dermal cylindroma patients had a median age of 72.5, 61.5, 
58 and 60 years at diagnosis, respectively. Notably, four patients (one cylindroma, one spiradenoma, one 
patient with a high-grade spiradenocarcinoma and a patient with both a cylindroma-spiradenoma hybrid 
hybrid tumour and a high-grade spiradenocarcinoma) were previously diagnosed with Brooke-Spiegler 
syndrome. Half of tumors (37/68; 54%) were located on the head and neck area while the remaining cases 
were from the trunk (19/68; 28%) or extremities (7/68; 10%). The tissue sites for the remaining 8% of 
tumors (5/68) were unknown. Formalin-fixed paraffin-embedded (FFPE) cores were collected from each 
tumor and DNA extracted, while uninvolved adjacent skin (epidermis/dermis/superficial subcutis) was used 
to obtain normal/germline DNA where available (referred to here as adjacent normal/germline). For several 
spiradenocarcinomas we analysed both low- and high-grade regions (Supplementary Data 1). DNA 
samples were whole-exome sequenced on the Agilent/Illumina platform at the Wellcome Trust Sanger 
Institute generating a median depth of 60x coverage (after duplicate removal and read clipping).  
 
The somatic mutational landscape of adnexal tumors 
DNA sequencing data from the 52 tumor/germline pairs was subjected to somatic variant calling (see 
Methods) resulting in the identification of 1124 somatic point mutations in exons of which 817 were protein 
altering and 307 were silent mutations. The number of somatic single nucleotide variants (SNVs) varied 
markedly between individual tumor samples (mean 21.6 mutations, range 2-144) (Fig. 1, Supplementary 
Data 2). In addition to SNVs, we also called 219 small insertion/deletions (indels) (Supplementary Data 
2). Recurrently altered cancer driver genes included CYLD (14 cases), NRAS (p.Q129E, p.Q61K in the same 
sample), AKT1 (p.E17K in three cases), TP53 (p.E286K, p.G266E, p.R248Q and indels p.D228Fs*20, 
p.R209Fs*6) and DNMT3A (p.R556M, p.R320*, E213_splice, E585_splice)(Fig. 1). All mutations shown 
were validated using high-depth (median depth of coverage 117x) targeted exome capture across all 
samples where DNA was available (Agilent design ID: S3065404) (Supplementary Data 1). To further 
validate our variant calls and to determine the accuracy of our whole-exome sequence capture analysis, we 
used our targeted exome data to assay a further 119 randomly selected somatic variants revealing an overall 
validation rate of 82%. For indels the validation rate was 73%. A pan-cancer analysis revealed that in 
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comparison to cancers sequenced by The Cancer Genome Atlas (TCGA), the tumors sequenced here have 
a low somatic point mutation burden in the exome and fall within the range of 0.04-2.88 mutations/Mb 
(Supplementary Fig. 1), a frequency similar to thyroid cancer and uveal melanoma. Generally, 
cylindromas were found to carry more mutations than the other tumor types (Wilcoxon test P = 0.0153). 
Potential associations between the number of somatic mutations and age, sex of the patient, and tumor site 
were examined using a generalised linear model. No significant relationships with any individual clinical 
feature were observed. An overview of the genomic landscape including all available clinical characteristics 
for these cases can be found in Supplementary Fig. 2. 
 
Identification of driver genes in adnexal tumors 
A typical tumor cell may contain tens to thousands of somatic mutations distributed across hundreds of 
genes. Only a handful of these genes when mutated confer a selective growth advantage and thus may 
facilitate the promotion of tumor growth12. We applied two independent driver gene discovery tools: 
IntOGen and dNdScv to detect potential driver genes in our adnexal tumor cohort 13, 14. The IntOGen driver 
gene prioritization framework combines scores from SIFT, PolyPhen2 (PPH2) and MutationAssessor 
(MA), to calculate the functional impact bias (FM bias) of mutations in genes against a background 
distribution 13, 15, 16, 17. Using this approach genes computed to have a significant functional impact score 
(OncodriverFM q value) are reported as drivers. dNdScv on the other hand is a maximum likelihood-based 
method used to quantify positive selection of genes mutated in cancer using the ratios of missense and 
disruptive mutations vs synonymous mutations. We performed driver gene analyses using both of the 
aforementioned workflows using somatic mutations from the cylindromas, spiradenomas and high-grade 
and low-grade spiradenocarcinomas. A consensus of these two approaches is reported here. CYLD and 
DNMT3A were identified as statistically significant driver genes in cylindroma. CYLD was also reported as 
a driver gene in spiradenoma, while the tumor suppressor gene TP53 was found to be significantly enriched 
with mutations in high-grade spiradenocarcinoma. Notably, ALPK1 was recurrently mutated at a hotspot 
position and was reported as a driver event in both spiradenoma (both methods) and spiradenocarcinoma 
(only by IntOGen), and is discussed in detail below. This mutation was absent from cylindromas. A 
complete list of the driver genes and significance values for each adnexal tumor type can be found in 
Supplementary Data 3. This table also provides the aggregate number of missense, nonsense and 
synonymous mutations identified in each gene.  
 
A recurrent ALPK1 mutation in spiradenoma and spiradenocarcinoma 
The ALPK1 (α-kinase 1) gene is a member of the α-kinase family and is located on chromosome 4q25 18. 
Recent studies have indicated that the expression of ALPK1 during infection/inflammation can result in the 
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activation of nuclear factor-kappa-B (NF-κB) signalling and downstream gene expression 19, 20. Somatic 
mutation of ALPK1 in 32/1397 lung cancer samples (2.29%) and 29/ 781 colorectal cancer samples (3.71%) 
has recently been reported 18 and ALPK1 has been shown to function as an oncogene in oral squamous 
cancers21. 
 
We discovered a recurrent somatic hotspot mutation in the alpha kinase domain of the ALPK1 gene 
(p.V1092A) in 7/16 spiradenomas, 2/8 high-grade and 2/6 low-grade spiradenocarcinomas (Fig. 1 & 2, 
Supplementary Data 2) from our discovery cohort. All mutations were validated using targeted gene panel 
sequencing (see Methods). The hotspot mutation (p.V1092A) was also validated via Sanger sequencing in 
8/11 of the aforementioned cases identified by whole exome sequencing. The position was also tested in 7 
wildtype samples, all of which were confirmed to be mutation negative (Supplementary Data 1). 
Interestingly, in several cases (n=5) we observed the ALPK1 p.V1092A mutation in the adjacent 
morphologically normal tissue (in addition to the tumor) from which the normal/germline DNA for somatic 
variant calling was extracted. The average mutant allele fraction of the mutation in these samples was 0.32 
suggesting that they are clonal or present in a significant proportion of cells. None of the other somatic 
mutations in the corresponding tumor sample were found in the sequence data from the adjacent 
morphologically normal tissue making extensive tumor to normal contamination unlike (see Methods). 
This mutation was also observed in sequence data generated from benign precursor regions (n=4) 
suggesting that the ALPK1 p.V1092A mutation may be an early founder/truncal mutation, or is associated 
with a field change, as has been widely reported for other cancers, particularly skin22. Interestingly, mutation 
of ALPK1 was mutually exclusive (q value 0.0014623) from mutation of CYLD 22, 24 (Fig. 1). To further 
confirm the presence of the ALPK1 p.V1092A mutation a further 10 spiradenoma tumor/normal pairs were 
tested via Sanger sequencing and the p.V1092A mutation was observed in six tumors.  
  
Mutation of CYLD in adnexal patients and tumors 
CYLD (CYLD Lysine 63 Deubiquitinase) encodes a cytoplasmic protein with three cytoskeletal-associated 
protein-glycine-conserved (CAP-GLY) domains and functions as a deubiquitinating enzyme and tumor 
suppressor25. CYLD regulates the NF-κB pathway, which plays important roles in cell growth and survival 
26, 27. Germline mutation of CYLD is associated with Brooke-Spiegler syndrome, which may present with 
cylindroma, cylindromatosis, trichoepithelioma and/or spiradenoma 2. Eleven of the twelve cylindroma 
patients we sequenced carried either germline or somatic protein altering mutations of CYLD. The final 
cylindroma case (PD29703a) was found to carry a somatic splice region mutation (16: 50815325 A/G) 
located three bases away from the splice junction. CYLD mutations were also found in 31% (5/16) of the 
spiradenomas (Fig. 1). All four patients with a prior Brooke-Spiegler syndrome diagnosis whose germline 
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we sequenced carried a germline CYLD mutation. The protein altering mutations in CYLD are shown in 
Fig. 2a. 
 
Promoter and regulatory mutations 
Cis- regulatory elements control the transcription of genes and mutations in these regions can potentially 
lead to aberrant protein production and tumorigenesis. Exome sequencing is not well equipped to detect 
cis- regulatory element mutations as it is designed to capture protein-coding regions. However, sufficient 
coverage (>10x read coverage) around exon boundaries allowed us to investigate the status of proximal 
regulatory elements such as promoters. Detected non-coding mutations were scored for pathogenicity 
weighting them with a CADD (Combined Annotation Dependent Depletion) variant deleteriousness score28 
(see Methods). Mutations were also annotated in the regulatory regions of known cancer driver genes. In 
this way, we identified mutations in the TERT promoter region (C228T and C250T) in four 
spiradenocarcinomas, known hotspot positions in other cancers 29. Somatic mutations in the proximal 
regulatory regions of other genes such as SPTA1, HMCN1 and COL11A1 were also detected 
(Supplementary Data 2).  
 
Mutational processes in adnexal tumors 
Somatic mutations in tumor cells may be the consequence of aberrant endogenous processes such as 
defective DNA repair or due to exogenous factors such as exposure to carcinogens. The imprint of a 
mutational process on DNA sequence is commonly referred to as a mutational signature 30. Analysis of 
mutational signatures has led to a better understanding of the underlying biological processes associated 
with a number of cancers and has also allowed patient stratification for therapy 31.  
To assess the presence of published human cancer mutational signatures in the catalogue of somatic 
mutations from adnexal tumors we used deconstructSigs (see Methods)32. This approach computes the 
weighted contributions of the 30 published COSMIC signatures and one additional unknown signature to 
the mutational catalogue of each sample. The heatmap in Fig. 3a represents the contribution of these 
signatures across all adnexal tumor subtypes. In more than a quarter (26.92%) of tumors the contribution 
of signature 1 was greater than 0.5 meaning most mutations in these samples can be attributed to this 
signature. Signature 1, is an endogenous mutational process associated with spontaneous deamination of 5-
methylcytosine, which is often correlated with age33. The mutation catalogue from cylindromas was also 
enriched for signature 7, which is predominantly found in skin cancers as a result of ultra violet (UV) light 
exposure. The predilection of cylindromas to form on the head and neck is likely to explain this signal. We 
also performed an analysis combining mutations for each tumor type together and again identified signature 
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1 and signature 7 in cylindromas, while several low-grade spiradenocarcinomas showed a signal for 
signature 26, which is thought to be associated with DNA mismatch repair 30. 
Somatic DNA copy number alterations 
The copy number status of our adnexal samples was assessed using Sequenza, an allele specific copy 
number analysis algorithm that uses matched tumor-normal pairs 34. Sequenza reported a total of 1,577 
somatic copy number changes (1,350 gains and 227 losses) across 52 tumors. Several high-grade 
spiradenocarcinomas showed large copy number changes, while low-grade spiradenocarcinomas 
demonstrated a comparably lower number of copy number events, although a larger number of samples 
will be required to fully explore the copy number landscape of these tumors. Cylindromas and spiradenomas 
generally showed few copy number changes, as did morphologically benign precursor regions. Genome-
wide copy number profiles across all subtypes are reported in Fig. 3b.    
 
The MYB-NFIB fusion in adnexal tumorigenesis 
A previous report has suggested a role for MYB-NFIB fusions in the pathogenesis of both adenoid cystic 
carcinoma and cylindroma 8, 9. Using dual-colour FISH we analysed 21 cases including 13 cylindromas, 7 
spiradenomas and 1 cylindroma-spiradenoma hybrid tumor in addition to an adenoid cystic carcinoma case 
known to carry the MYB-NFIB fusion as a control. This analysis revealed that, despite previous reports, 
none of the cylindromas were found to carry the fusion event 8. The MYB-NFIB fusion was also absent from 
the spiradenomas and cylindroma-spiradenoma hybrid tumor (Fig. 4a-b, Supplementary Figs. 3 & 4). 
Overexpression of MYB was, however, confirmed in cylindroma and spiradenoma cases using 
immunohistochemistry (Fig. 1 & Supplementary Data 4) suggesting other mechanisms of gene 
overexpression are operative.  
 
Germline analysis of adnexal tumor patients 
As mentioned above, we identified germline CYLD mutations in all four patients previously diagnosed with 
Brooke-Spiegler syndrome. A germline CYLD mutation (in-frame deletion) was also detected in an 
additional patient with no prior Brooke-Spiegler syndrome diagnosis (PD29699) (Fig. 1). To extend the 
analysis of germline variation in patients from our cohort we used samtools mpileup and the bcftools variant 
genotyping strategy 35. We assessed the coding mutation burden per gene using a Fisher’s exact test (see 
Methods) (Supplementary Data 2) 36 using variants from the 42 cases where adjacent normal/germline 
exome sequence had been generated. From this analysis CYLD was found to carry significantly more 
mutations than expected (Benjamini-Hochberg (BH) adjusted p-value 0.01), reconfirming its well-
established role as an adnexal tumor predisposition gene. We also detected a significantly high number of 
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mutations in FAT4, BFAR, CRB2 and PEX14 (BH adjusted p-value <0.05). FAT4 is a member of human 
FAT gene family which encodes a large transmembrane protein consisting of multiple extracellular cadherin 
domains and a cytoplasmic domain that can interact with signalling molecules 37. This gene is homologous 
to fat in Drosophila, a known tumor suppressor gene 38. It should be noted, however, that FAT4 has been 
reported as ‘disease-associated’ in several studies, which might suggest a high rate of polymorphism 39, 40, 
41. BFAR, the bifunctional apoptosis regulator, plays a role in the regulation of cell death and in this way 
could contribute to tumorigenesis 42. Notably for FAT4, BFAR, CRB2 and PEX14 we did not identify 
somatic mutations in the wildtype allele of these genes in the cases carrying germline mutations suggesting 
that if they are contributing to tumor formation they most likely do not function as classical tumor 
suppressors. Further, samples with germline variants in these genes also had germline or somatic loss-of-
function alleles of CYLD, making these less likely candidate predisposition genes. We next asked if 
mutations of known pathogenicity were found in the germline of any of our adnexal cases. In this way we 
found 14 pathogenic or likely pathogenic variants including missense mutations in PTEN and NSD1 
(Supplementary Data 2) (ClinVar database (dbSNP build 144). The PTEN mutation we found has been 
reported in a single individual in ClinVar with a Cowden-like syndrome and changes a phenylalanine to a 
serine (P200S). This substitution occurs at a position that is conserved across species. In silico analysis 
predicts that this variant is probably damaging to protein structure/function. Missense (disease causing) 
mutations in nearby residues (V191G, M198K, T202I, M205V, S207R) have been reported, supporting the 
functional importance of this region of the protein. That said, the clinical records for our patient (PD29681) 
do not mention Cowden syndrome and the patient was 81 when their skin tumor was removed. Further, we 
did not detect a somatic mutation in the other allele of PTEN. In contrast our patient carrying a germline 
mutation in NSD1 carries a well-established SOTO syndrome-associated allele (R2017W) predicted to be 
disruptive of SET domain function43, 44. Thus, of the 42 adnexal patients analysed here we have shown that 
five patients carry germline mutations in CYLD and propose several other candidate genes as mediators of 
germline susceptibility for follow-up studies.  
 
Analysis of tumors without matched germline DNA 
For 52 of the samples in our cohort we had matched tumor/adjacent normal-germline pairs (as described 
above). Matched germline DNA was not available for a further 23 samples (15 patients; 3 cylindroma, 1 
spiradenoma, 1 cylindroma-spiradenoma hybrid, 3 low-grade spiradenocarcinoma, 7 high-grade 
spiradenocarcinoma) and thus we used the tumor sequences from these cases as a validation cohort to look 
for variants in genes identified from the abovementioned analyses. We first called variants against an 
unmatched normal sample (Supplementary Data 1) and then filtered these data using variants in the ExAC 
database36 (with an allele frequency > 0.0001) and with variants from an in-house panel of 100 normal 
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germline exomes. We next focused on genes identified from our analysis of the discovery cohort (see 
Methods) revealing ALPK1 p.V1092A mutations in one cylindroma-spiradenoma hybrid, two low-grade 
spiradenocarcinomas and one spiradenoma. Loss-of-function mutations were also detected in CYLD in 
cylindroma cases (PD29695a, PD29696a, PD29700a) and in one low-grade spiradenocarcinoma 
(PD29676a). Tumors from two high-grade spiradenocarcinoma patients (PD29684, PD29685) were found 
to carry frameshift deletions in TP53 (p.P191fs*54 and p.T329fs*8). For each patient, the respective 
changes were present in all collected tumor samples indicating they maybe germline in origin or occur early 
in tumor development. An overview of the driver gene landscape and clinical characteristics of all 75 
tumors/samples can be found in Supplementary Fig. 5. 
         
Functional studies of the ALPK1 p.V1092A variant 
Given the role of ALPK1 in the regulation of the NF-κB pathway in infection we next asked if the ALPK1 
p.V1092A variant could activate NF-κB signalling and thus substitute for mutation of CYLD. To do this we 
generated full-length ALPK1 wildtype and p.V1092A mutant cDNA constructs in an expression vector. 
Since adnexal cell lines do not exist we transfected these constructs into a panel of six NF-κB reporter cell 
lines (Supplementary Fig. 6). Analysis in this way showed that the mutant construct activated NF-κB 
reporter activity to a considerably higher level than the wildtype construct in MCF7, WM266-4 and 
WM1552C cells, consistent with a role for this variant in driving tumor growth through the NF-κB pathway, 
akin to mutation of CYLD. To further confirm that the p.V1092A ALPK1 mutation activates NF-κB 
signalling we performed immunohistochemistry and found p65 staining of ALPK1 mutant spiradenomas 
was indistinguishable from staining of CYLD mutant cylindromas (Fig.4c).  
 
Discussion  
The analysis of adnexal tumors in this study yielded several remarkable results. Firstly, we identified a 
recurrent somatic missense ALPK1 mutation (p.V1092A) in the kinase domain of this alpha-kinase and 
demonstrated that this mutation activates NF-κB signalling in cell reporter systems. Importantly, ALPK1 
has previously been suggested to function as an oncogene45. Since kinases can be readily inhibited this 
mutation represents a potential therapeutic target, which might be particularly advantageous in the 
advanced/metastatic setting, where effective treatments have not been identified. Secondly, we found driver 
genes not previously associated with adnexal tumors. For example, statistical analyses revealed significant 
enrichment of mutations in DNMT3A in cylindromas, a gene previously linked to haematopoietic 
malignancies, where it plays a role in the regulation of DNA methylation 46, 47. Further studies will be 
required to establish the direct functional role of these mutations in adnexal tumors and their effect on the 
epigenetic landscape. Mutations in genes such as AKT1, BCOR and PIK3R1 were also observed and these 
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genes may also contribute to tumor development. In keeping with previous studies, we found frequent 
mutation of the CYLD gene7, 48. Somatic or germline CYLD mutations were found in 12/12 cylindroma 
patients (matched tumour-germline cases) with mutations also being observed in spiradenoma and high-
grade spiradenocarcinoma cases. Notably, these mutations were mutually exclusive from the 
abovementioned ALPK1 variant. As the aetiology of adnexal tumors is unknown we performed a mutational 
signatures analysis. This revealed the presence of signature 1 across all tumor types, which is age-
associated, but also the UV-associated signature 7 in cylindromas, presumably because these tumors are 
generally found on the head and neck. There was also some suggestion of signature 26, associated with 
mismatch repair, in low-grade spiradenocarcinomas. Tumors in our adnexal collection were not only low 
in terms of their somatic mutation burden but also appeared to lack significant copy number alterations, the 
exception being several of the high-grade spiradenocarcinomas which, compared to other adnexal tumors, 
were replete with copy number gains. Finally, we identified germline variants in CYLD that have not been 
described previously, and thus represent new pathogenic alleles. We also found cases with pathogenic 
variants in the ClinVar database including in PTEN and NSD1, suggesting potential adnexal tumor 
predisposition alleles. The identification of a patient with an NSD1 mutation, which is associated with Sotos 
syndrome, is of particular interest since previous case reports suggest adnexal tumors in some patients with 
this condition 49. These insights should be explored in larger case series. 
 
In summary, our paper reports the most comprehensive picture of the genomic landscape of adnexal tumors 
to date, including driver genes, copy number alterations and a potentially actionable kinase mutation and 
mutational signatures. We hope these studies will help inform the management of patients with these 
malignancies.  
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Methods 
 
Patients and samples 
Samples for whole exome sequencing (WES) and targeted gene panel sequencing (TGPS) were collected 
from 57 patients and divided into a discovery (tumor/adjacent normal-germline pairs) and a validation 
cohort (tumor only). The discovery cohort contained 52 tumors/samples and matched adjacent 
normal/germline DNA from 42 patients. This cohort was used for the initial genomic profiling and driver 
gene analyses. Mutations from 23 additional samples (15 patients) from the validation cohort were also 
reported. From some lesions we were able to obtain high-grade and low-grade spiradenocarcinoma regions 
which were sequenced and analysed separately. A detailed description of each case/sample can be found in 
Supplementary Data 1. All diagnoses were confirmed by two independent pathologists. Ethical approval 
was obtained from the West Lothian Tissue bank.  DNA was extracted using Qiagen kits.  
 
Whole-exome sequencing 
Exonic DNA was captured using the Agilent whole-exome capture kit (SureSelect All Exon V5). Captured 
material was indexed and sequenced on the Illumina Hiseq2500 platform at the Wellcome Sanger Institute 
to a median depth of 60x. Raw 75 bp pair-end sequencing reads were aligned with BWA (v0.7.12) to the 
GRCh37 human reference genome producing a single Binary Alignment Map (BAM) file for each sample 
50. Duplicated reads resulting from PCR were marked with BioBamBam (v2.0.54) 35, 50, 51.  
 
Targeted gene panel resequencing 
To confirm our findings from whole exome sequencing we validated mutations in the top recurrently 
mutated genes using panel sequencing (Supplementary Data 5). Genomic regions for 550 genes were 
captured using Agilent custom pulldown baits. Captured material was indexed and sequenced on the 
Illumina Hiseq4000 platform to a median depth of 117x. Raw 75 bp pair-end sequencing reads were 
processed using the same pipeline as used for whole-exome sequencing described above.  
 
Somatic variant detection 
Somatic variants were detected using CaVEMan, an expectation maximization–based somatic substitution 
detection algorithm 52. To ensure tumor and normal were paired correctly for somatic variant calling and to 
avoid any possible sample swap we used genotype data from 20,000 randomly selected germline variants. 
A pairwise correlation coefficient between each sample pair is shown in Supplementary Fig. 7. Candidate 
somatic variants were then filtered for quality and to remove common population variants (ExAC allele 
frequency > 0.0001). Small insertion and deletion (indel) detection was performed using the cgpPindel 
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pipeline (v0.2.4w) 53. Detected indels were then filtered for quality, sequence coverage in both tumor and 
normal, strand bias, and for overlap with known simple repeats or indels in an in-house normal panel.  
 
Variant quality control for FFPE artefacts 
Formalin fixation of tumor biopsies can have a detrimental impact on DNA integrity and introduce 
C>T/G>A sequencing artefacts54. These artefacts are more frequently observed at a 0.01-0.10 mutant allele 
fraction (MAF) 54. To remove these variants, we used the following filters:  
 
- Tumor read depth (TRD) and adjacent normal/germline read depth (NRD) greater than or equal to 
10. 
- Mutation with MAF <= 0.10 is kept only if TRD and NRD is greater than equal to 30.  
- Mutation with MAF <= 0.05 is kept only if TRD is greater than or equal to 100.  
 
After filtering our somatic point mutation validation rate from the whole exome sequencing data was 82% 
for SNVs and 73% for indels as confirmed by targeted sequencing.  
 
Mutual exclusivity analysis of ALPK1 and CYLD mutations 
Mutual exclusivity between ALPK1 and CYLD was evaluated using the DISCOVER23 co-occurrence and 
mutual exclusivity analysis tool. Somatic point mutations and small indels from all 52 tumors were 
combined into a single 𝑁𝑥𝑀binary data matrix, where each cell value 𝑉௜,௝ (i=1…N [Number of genes], 
j=1...M[Number of tumors] ) indicated the status of gene i in tumor j. 𝑉௜,௝ = 1 if gene i is mutated in tumor 
j and 0 otherwise. Alteration status of all genes across all tumors was used to generate a null distribution 
for background alternation rate estimation. Finally, we computed pairwise mutual exclusivity between any 
two genes mutated in more than two tumors, taking the null distribution in to account.  
 
Germline mutation burden analysis  
We applied an exome-wide Fisher’s exact test to assess the significance of observing n mutations in gene 
X in our 42 germline samples, given gene X has a mutation rate of Y in a control population. To select an 
appropriate control population, we performed a principal component analysis using 2504 individuals across 
multiple populations from the 1000 Genomes Project phase355. We randomly selected 2000 single 
nucleotide polymorphic variants (SNPs) and to mitigate the impact of population specific rare variants we 
only selected SNPs with a population allele frequency between 0.1 and 0.7. PCA analysis revealed that all 
42 patients with tumor-germline pairs were of European descent (Supplementary Fig. 8). Therefore, 
polymorphic variants from the ExAC database from individuals of non-Finnish European descent were 
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used as a negative control. Readers should be mindful of the strengths and weakness of such an approach56.  
A Combined Annotation Dependent Depletion (CADD) score filter was applied and only variants with a 
CADD score above or equal to 15 were taken forward for burden testing. We also ensured that only variants 
with sequence coverage of >10x in both the case and control data set were used. Finally, we applied a 
Fisher’s exact test on every gene to estimate the likelihood of observing n deleterious mutations given the 
background mutation rate of that gene in the control population. The Benjamini-Hochberg method was used 
to correct for multiple testing and only genes with an adjusted p-value less or equal to 0.05 were reported 
as significant. 
 
Mutational signature analysis 
To reduce the potential impact of artefacts from 5-methycytocine deamination and degradation in our FFPE 
samples, low allelic fraction mutations (mutant allele fraction < 0.10 and read depth < 10) were removed 
from the signature delineation process (as outlined above). Somatic point mutations were then mapped to 
the 96 possible trinucleotide contexts taking into account the probability of each mutation occurring in each 
trinucleotide within the human genome. We then applied deconstructSigs, a multiple linear regression-
based algorithm to reconstruct the mutation profile of each tumor sample using a linear combination of 
predefined mutational signatures 32. Thirty human cancer signatures as defined in Alexandrov et.al, were 
used for the reconstruction and one “unknown” signature 30.  
 
DNA copy number analysis 
To estimate allele-specific copy number profiles we used the Sequenza software package (v2.1.0), a 
probabilistic model-based algorithm applied to segmented average depth ratio (tumor versus normal) and 
B allele frequency34. Pre-processing and analysis with Sequenza were performed as described in the 
Sequenza documentation and fitted models were manually examined. For four tumor-normal pairs default 
fitted model suggested very high ploidy. However, after manual inspection of the depth ratio and B-allele 
fraction data an alternative solution closer to ploidy 2 was selected due to lack of evidence for high ploidy.  
 
Gene fusion analysis by Fluorescence in situ Hybridization 
Fusion gene analysis of the paraffin-embedded tissue sections was performed using the MYB-NFIB 
fusion/translocation FISH probe kit from CytoTest, following the manufacturer protocol. The MYB 5’ probe 
covers the entire MYB gene along with upstream (5’) and some downstream (3’) genomic sequences. The 
NFIB 3’ probe covers the 3’ (end) portion of the NFIB gene along with some adjacent genomic sequence. 
An adenoid cystic carcinoma (PD_ACC) case known to carry the fusion was used as a positive control.  
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ALPK1 hotspot validation using Sanger sequencing 
DNA was extracted as above for exome sequencing. The region of interest of ALPK1 was amplified using 
ThermoFisher Platinum HiFi Taq DNA polymerase (following manufacturer’s instructions) using the 
oligos shown below. Amplified products were sequenced by Sanger Sequencing (Eurofins) using the same 
oligos. Sequence traces were analysed by visual inspection.  
  
ALPK1 Forward: 5’ TTGATCTCCTCTCTCTTACTCCA 3’ 
ALPK1 Reverse: 5’ ATGCTAGCCTGATTATGTGGAA 3’ 
 
Functional analysis of ALPK1 mutation by NFkB reporter assays 
MCF-7, T-47D, WM266-4, WM1552C, PANC-1 and MIA PaCa-2 cells (obtained from the American Type 
Culture Collection [ATCC]) were seeded in T25 flasks to obtain 80% confluence for transfection. The 
following day, cells were transfected with 1.5µg WT or Mut ALPK1 cDNA and 1.5µg RFP using 
the Effectene kit (Qiagen), according to the manufacturer's protocol. After 24hr, 4,000 cells were 
transferred to six wells per line/construct in a 384-well TC-treated PelkinElmer Cell Carrier Ultra plate. 
After a further 24hr, cells were fixed with formaldehyde/PBS at a final concentration of 4% for 10 min 
at 37 °C . Cells were permeabilised in 0.2 % TritonX-100/PBS (Sigma Aldrich) for 10 min and blocked in 
2 % BSA/PBS for 1 hr at RT. Cells were stained with rabbit anti-p65/RELA NF-κB (Abcam; cat 16502; 
1:500) for 2hr at RT then Alexa 647 goat anti-rabbit IgG (Invitrogen, 1:500) for 1hr at RT. Cells were 
stained with 10µg/ml Hoechst (Sigma Aldrich; cat 33258) for 10 min at RT.  Images were taken using 
the PerkinElmer Opera confocal microscope and a 20x air objective. Image analysis was performed using 
custom image analysis scripts with PerkinElmer’s Columbus 2.6.0 software. 
 
MYB expression by immunohistochemistry  
MYB overexpression in cylindromas has been reported in several earlier studies57. We attempted to assess 
MYB expression status in 26 samples (11 cylindromas, 6 spiradenomas and 9 high-grade 
spiradenocarcinomas) using immunohistochemistry (IHC) (Supplementary Data 4). IHC was performed 
on 4-μm-thick formalin-fixed paraffin-embedded whole-tissue sections following antigen retrieval with 
Target Retrieval solution (pH 6.1; Dako, Carpinteria, CA, USA) in a pressure cooker using a rabbit 
monoclonal anti-MYB monoclonal antibody (1:200 dilution; clone EP769Y; Abcam, Cambridge, MA, 
USA) and the Envision+ polymer detection system (Dako). Immunohistochemistry for p65 was performed 
using an anti-NF-κB p65 antibody (1:5000 dilution; clone D14E12; Cell Signaling Technology, Danvers, 
MA, USA) as described for MYB above.  
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Data availability 
The data has been accessioned under the study EGAS00001001799 in the European Genome-phenome 
Archive. Source Data File 1 provides all of the variant calls in MAF and VCF format.  
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Legends to Figures  
 
Fig. 1: The driver gene landscape of adnexal tumors. Genetic data for the 52 cases where matched 
tumor/normal DNA sequencing data was available. Additional cases are shown in Supplementary Fig. 5. 
The germline and somatic mutations in this plot were validated by high-depth targeted exome sequencing. 
Only mutations in coding regions are shown except for TERT promoter variants and the splice region 
mutation in CYLD. Please note PD30271 and PD29730 are the same patient who had multiple tumors 
analysed. 
 
Fig. 2: Mutations identified in CYLD and ALPK1. Variants in CYLD (A) and ALPK1 (B) against the 
translation of the longest transcript of these genes (ENST00000458497.5 & ENST00000311559.13). 
Protein domains are from UniProt. All of the variants shown were validated by high-depth targeted exome 
sequencing. Adjacent normal represents morphologically normal tissue from the same block as the tumor 
which was used as a germline sample for somatic variant calling. Variants in red were called somatically. 
Variants in green were called from the adjacent normal tissue. The color of the circles indicate tumor/tissue 
type. The somatic splice region mutation in PD29703a in CLYD is not shown. C. Protein alignment of 
ALPK1 across vertebrates. The conservation score represents constrained elements in multiple alignments 
by quantifying substitution deficits. The arrow indicates the position of the p.V1092 residue in humans.  
 
Fig. 3: The somatic genetic landscape of adnexal tumors. A). The contribution of published mutational 
signatures in adnexal tumors detected using deconstructSigs 32. Total contribution per sample adds up to 
one. For this analysis we used all variants including those in non-coding regions such as 5’ and 3’ UTRs.  
B). The copy number landscape of adnexal tumors. This analysis was performed using Sequenza to define 
the absolute copy number for chromosomal segments. These analyses were performed using the tumors 
shown in Fig. 1. 
 
Fig. 4: Assessment of the MYB-NFIB fusion and p65 expression in adnexal tumors. A). Fluorescence 
in situ hybridization (FISH) imaging of the MYB-NFIB fusion in an adenoid cystic carcinoma and 
assessment in cylindroma samples. Previous reports have suggested that adnexal tumors such as cylindomas 
carry MYB-NFIB fusions which have been associated with MYB overexpression 8. Left panel shows an 
adenoid cystic carcinoma, which is positive control for the fusion event. Yellow signal results from the 
overlap of the green NFIB probe and red MYB probe. Right panel: a representative cylindroma which was 
fusion negative. B). Representative histopathological images of a cylindroma at 100x magnification, 
spiradenoma at 100x magnification, high-grade spiradenocarcinoma at 200x magnification and a low-grade 
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spiradenocarcinoma at 200x magnification. C). p65 immunohistochemistry of a CYLD mutant cylindroma 
(left) and an ALPK1 p.V1092A mutant spiradenoma (right) at 20x magnification.  
